Head, shoulders, knees and toes but nary a doji.
I love to hear a quant explain the movements of MDXG even retrospectively.
Here's to $15 in '14.
How'd you like to the folks who paid $.77 more per share than yesterday's close? After market trading is not for rookies.
9,000 shares from 8.01 to 8.57 but a bunch of small trades at the top. I'm guessing buyers putting in market orders and getting exactly that. Very expensive way to buy stock.
I don't have any better insight than you but what would move it 50%+ between now and 1/31? I hope you're right but can't identify a particular catalyst. .
Think you're high but hope you're not. I'm guessing a device company and the one they have distribution agreement with currently seems to be a good candidate.
Apparently he's reluctant to add Amniofix sales until FDA approval is recieved. I don't believe we'll be around in 2015.
I had talked a friend into buying a couple of months ago. He was bemoaning the the fact that he had written call options on half his position which called away last week.. The good news is he paid for a new car with his gain and option premium. He's now repurchased the shares at a signifcant premium to his original shares and is now a "true believer".
Bruce Jackson of Lake Street Capital raised his target to $9 based on $156 million 2015 sales. He estimates that Amniofix could add $75 million to the $156 million. Hope he's right.
Really nice consolidation going on today in the overbought area. Is this referred to among the quants, elves, etc. as shoulders, heads or some other body part? Just trying to be able intelligently converse who believe in reading tea leaves.
Zacks regularly demonstrates the limitations of only relying on quantitative analysis. In addition, they have MDXG classified as a medical device company. In that same data base I bet they've got Boston Scientific, Medtronic, Abbot Labs, etc. But the really screwy part is that today they're recommending OSIR over MDXG.
I don't think we bust $10 in 2013 but do sooner than I was expecting. I think this offering helps make us more of an institutionally attractive stock. I bought stock this AM (missed the low) because I thought this was such a bullish move. I was telling one of my kids in the institution investment industry today about the offering. She's calling Cannacord to see about buying in size at the offering. She's been following it but couldn't buy because of some silly parameters they are limited by.
You're right. I liked him even more than I like Jeff Francoeur.He was a product of the East Cobb County baseball machine that's produced 10 or 11 MLB players The scuttlebutt was that John Schuerholz thought as injury prone as McCann has been they wouldn't get their money out of him. Too bad the same calculus wasn't employed when they signed Uggla. I watch Bill DeWitt, the owner of the Cardinals, put together WS teams year end and year out and rarely bust the top 10 in salary and in a small market. He's the model John Malone and John Schuerholz ought to study. The Braves do have an excellent farm team system but then go out and sign Ugglas.
I don't see adding cash to the balance sheet as making MDXG more attractive. Most potential buyers have all the cash they need an probably are looking for places to deploy it. My guess is the offering is to help fund product expansion, possible strategic (what other kind would they do?) acquisitions and increase the float to accomodate more insititutional investors. My opinion and $3.50 will get you a large (or whatever that faux Italian work Starbucks uses) cup of coffee.
I bought this AM for me and my kids. I was hoping we'd get another opportunity but didn't think this would be the catalyst. We used Genuity on a micro cap IPO two years ago. They did a good job placing the shares but were a little weak supporting the price. Probably had to do more with the company than the underwriter.
Zacks'opinion reminds of a Louis Rukeyser interview with a quant. He asked the quant why he never met any rich quants. Had Zack's been around then, Rukeyser would have asked if anyone ever got rich following Zachs' recommendations.
I'm thinking some of this is hedging of existing positions. I was thinking of writing some calls but the way we've been moving around, I could get called out and leave all sorts of profits on the table.
I was really wrong on my guess as to what the response would be to the FDA.. I thought the FDA would come back as they did and require more work but I was thinking we would get a 10% to 20% sell off and get another buying opportunity. Looks like the market is getting more sophisticated regarding our little company. DARN IT!
I'm still thinking we'll see some mid 6s again at least intraday.
That explains Zacks' overbought call this morning. Of course, based on Zacks algorithms I'll be dumping my entire position so I can buy it all back 15 cents cheaper on Monday
One way to look at the respective results of these two companies is to compare the use of capital. OSIR has created $566 million of market capital while employing $279 million of shareholder equity. MDGX current market cap is $635 million generated by $89 million of shareholder equity. Based on this snapshot, our management has rewarded us much more handsomely than the brain trust at OSIR.
And even better news, Tensgut will be reporting back regarding those "personal reasons" for Mills' departure. It will be as well researched as his opinions.